Ustekinumab Successful Refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti- (anti-TNF) treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

Indeed, around 42% of patients achieved full clinical remission at 22 weeks after ustekinumab induction and maintenance.

“A of patients with moderate-to-severe Crohn’s disease do not have a response to treatment with TNF antagonists, and among patients who do have a response, it is often not sustained or side effects require discontinuation of therapy,” study co-author (, La Jolla, USA) and colleagues comment.

Noting that preclinical studies have implicated interleukin-12 and -23 in the pathophysiology of Crohn’s disease, they performed a clinical trial of a corresponding antagonistic , ustekinumab.

The phase II clinical trial involved in 658 patients with moderate-to-severe Crohn’s disease that was resistant to TNF treatment. During the induction phase, 526 patients were randomly assigned to receive intravenous ustekinumab (at a dose of 1, 3, or 6 mg/kg) and 132 to receive placebo.

Real Full article Ustekinumab success in refractory Crohn’s disease

News-Medical.net
By , medwireNews Reporter. Patients with Crohn’s disease who have failed to respond adequately to anti-tumor necrosis factor (anti-TNF) treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind,

About Rob Hill

In 1994, Rob was a fit, healthy 23-year-old, an amateur runner and athlete. Until that time, he had never really been sick. He didn’t even have a regular doctor. When the illness started, it progressed rapidly. Daily diarrhea. Sustained stomach cramps. The diagnosis was Crohn’s disease, an inflammatory condition of the digestive tract. It got worse, and his weight plummeted from 185 to 105 pounds. After a year and a half, it became clear that his large intestine, his colon, needed to be removed. Rob decided he had to do something about it. The Seven Summits campaign, which we call “No Guts Know Glory” grew from Rob’s love of sport, adventure and the outdoors. By taking it to the extreme, and on a global basis, Rob hopes to show people everywhere that having these diseases or having an ostomy, like Rob does, shouldn’t stop you from leading a full life. You may not be able to climb mountains, but there are so many other things you can do. To further this goal, Rob started the Intestinal Disease Education and Awareness Society (IDEAS), from his home base in Vancouver, British Columbia.

Leave a Reply